-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78

Benzinga·11/04/2026 23:34:46
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.